🇺🇸 FDA
Pipeline program

Tafamidis round 2, Tafamidis round 1, Tafamidis oblong

B3461114

Phase 1 small_molecule active

Quick answer

Tafamidis round 2, Tafamidis round 1, Tafamidis oblong for aransthyretin amyloid cardiomyopathy is a Phase 1 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
aransthyretin amyloid cardiomyopathy
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials